1. Search Result
Search Result
Results for "

TNKS

" in MedChemExpress (MCE) Product Catalog:

64

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

2

Recombinant Proteins

1

Antibodies

13

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-23338

    PARP Others
    TNKS-2-IN-1 (Compound 13g) is a TNKS-2 inhibitor. TNKS-2-IN-1 inhibits TNKS-1 and TNKS-2 with IC50s of 259 nM and 1100 nM .
    TNKS-2-IN-1
  • HY-13990

    TNKS656

    PARP Apoptosis Cancer
    NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.
    NVP-TNKS656
  • HY-156332

    PARP Cancer
    TNKS-2-IN-2 is a potent and selective inhibitor of TNKS2 with an IC50 of 22 nM .
    TNKS-2-IN-2
  • HY-173480

    PARP Cancer
    TNKS-IN-3 (Compound 6) is a TNKS2 inhibitor (Ki: 8.5 nM). TNKS-IN-3 has good activity (IC50: 71 nM) and can effectively inhibit the WNT/β-catenin signaling pathway. TNKS-IN-3 can be used in the research of diseases such as cancer and fibrosis .
    TNKS-IN-3
  • HY-12601

    TNKS-IN-22

    PARP Cancer
    TNKS 22 (compound 22) is an orally active and selective tankyrase inhibitor. TNKS 22 inhibits TNKS1 and TNKS2 with IC50s of 0.1 and 4.1 nM, respectively .
    TNKS 22
  • HY-12602

    PARP Cancer
    TNKS-IN-4 (compound 49) is an orally active tankyrase (TNKS) inhibitor with IC50 values of 0.1 nM and 7.6nM for TNKS1 and TNKS2, respectively. TNKS-IN-4 can be used for study of APC-mutant colorectal cancer .
    TNKS-IN-4
  • HY-13990G

    TNKS656

    PPAR Apoptosis Cancer
    NVP-TNKS656 (GMP) is NVP-TNKS656 (HY-13990) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.
    NVP-TNKS656
  • HY-172747

    PARP Cancer
    TNKS-2-IN-3 (Compound 5) is a selective competitive tankyrase 2 (TNKS2) inhibitor with an IC50 value of 0.3 nM, showing over 20-fold selectivity over TNKS1 and more than 100-fold selectivity over PARP1/2. TNKS-2-IN-3 stabilizes axin and suppresses the Wnt/β-catenin pathway by inhibiting TNKS2-mediated ADP-ribosylation, exhibiting antiproliferative activity in colorectal cancer cells. TNKS-2-IN-3 is proming for rasearch of solid tumors with aberrant Wnt pathway activation, such as colorectal cancer .
    TNKS-2-IN-3
  • HY-153259

    TNK1 PARP Cancer
    TNKS1/2-IN-2 (Compound 21) is a potent and selective tankyrases inhibitor. TNKS1/2-IN-2 exhibits IC50 values of 4 nM and 63 nM against TNK1 and TNK2 in the enzymatic assay, respectively. TNKS1/2-IN-2 inhibits proliferation of A549 and H292 cell lines with IC50 values of 39.5 nM and 12.8 nM, respectively. TNKS1/2-IN-2 can be used for the research of cancer .
    TNKS1/2-IN-2
  • HY-12577

    PARP Cancer
    TNKS1/2-IN-1 is a potent tankyrase TNKS1/2 inhibitor with pIC50s ranging from 7.1-8.2. TNKS1/2-IN-1 can be used for research of cancer, fibrosis, and other hyperproliferative diseases .
    TNKS1/2-IN-1
  • HY-117700

    Wnt PARP Cancer
    TNKS-IN-2 (compound 40) is a potent and selective tankyrase (TNKS) inhibitor with pIC50 values of 8.1, 7.0 for TANKS and Wnt, respectively .
    TNKS-IN-2
  • HY-RS14840

    Small Interfering RNA (siRNA) Others

    Tnks Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnks gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Tnks Mouse Pre-designed siRNA Set A
    Tnks Mouse Pre-designed siRNA Set A
  • HY-RS14841

    Small Interfering RNA (siRNA) Others

    Tnks Rat Pre-designed siRNA Set A contains three designed siRNAs for Tnks gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Tnks Rat Pre-designed siRNA Set A
    Tnks Rat Pre-designed siRNA Set A
  • HY-RS14839

    Small Interfering RNA (siRNA) Others

    TNKS Human Pre-designed siRNA Set A contains three designed siRNAs for TNKS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TNKS Human Pre-designed siRNA Set A
    TNKS Human Pre-designed siRNA Set A
  • HY-RS14844

    Small Interfering RNA (siRNA) Others

    Tnks2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnks2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Tnks2 Mouse Pre-designed siRNA Set A
    Tnks2 Mouse Pre-designed siRNA Set A
  • HY-RS14845

    Small Interfering RNA (siRNA) Others

    TNKS2 Rat Pre-designed siRNA Set A contains three designed siRNAs for TNKS2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TNKS2 Rat Pre-designed siRNA Set A
    TNKS2 Rat Pre-designed siRNA Set A
  • HY-RS14843

    Small Interfering RNA (siRNA) Others

    TNKS2 Human Pre-designed siRNA Set A contains three designed siRNAs for TNKS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TNKS2 Human Pre-designed siRNA Set A
    TNKS2 Human Pre-designed siRNA Set A
  • HY-RS14842

    Small Interfering RNA (siRNA) Others

    TNKS1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TNKS1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TNKS1BP1 Human Pre-designed siRNA Set A
    TNKS1BP1 Human Pre-designed siRNA Set A
  • HY-146336

    PARP Apoptosis Cancer
    PARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual PARP-1, PARP-2, TNKS1 and TNKS2 inhibitor with IC50 values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 exhibits favorable synergistic antitumor efficacy and induces apoptosis .
    PARP1/2/TNKS1/2-IN-1
  • HY-123851

    M2912

    PARP Cancer
    MSC2504877 (M2912) is a potent and orally active tankyrase inhibitor with IC50s of 0.0007, 0.0008, 0.54 µM for TNKS, TNKS2, PARP1, respectively. MSC2504877 increases the expression of AXIN2 and TNKS protein levels and decreases β-catenin levels. MSC2504877 shows anti-tumor activity .
    MSC2504877
  • HY-145111

    Tyrosinase Cancer
    TNK2-IN-1 is a TNK2 inhibitor. TNK2-IN-1 has an IC50 of 224 nM for TNK2. TNK2-IN-1 can be used for the research of cancer .
    TNK2-IN-1
  • HY-118731

    Reverse Transcriptase Infection
    TNK-6123 is a potent Emivirine (HY-15353) analogue with improved activity against drug-resistant HIV mutants. TNK-6123 improves activity against Lys103Asn mutant RT .
    TNK-6123
  • HY-U00422
    K-756
    2 Publications Verification

    PARP Cancer
    K-756 is a direct and selective tankyrase (TNKS) inhibitor, which inhibits the ADP-ribosylation activity of TNKS1 and TNKS2 with IC50s of 31 and 36 nM, respectively.
    K-756
  • HY-173349

    PARP Cancer
    TDI-012804 is a TNKS2 inhibitor that selectively inhibits intracellular endogenous TNKS2 protein. TDI-012804 increases the expression of AXIN1 protein in cells that are heterozygous (Tnks1HET) and completely knocks out (Tnks1KO) for TNKS1. TDI-012804 inhibits the proliferation of ApcQ1405X/Tnks1KO organoids (EC50 of 59.1 nM) and is selectively toxic to Tnks1KO AKP-G12D and AKP-G13D organoids .
    TDI-012804
  • HY-12418
    Stenoparib
    2 Publications Verification

    E7449; 2X-121

    PARP Cancer
    Stenoparib (E7449) is a potent PARP1 and PARP2 inhibitor and also inhibits TNKS1 and TNKS2, with IC50s of 2.0, 1.0, ~50 and ~50 nM for PARP1, PARP2, TNKS1 and TNKS2, respectively, using 32P-NAD + as substrate.
    Stenoparib
  • HY-13968
    JW 55
    5 Publications Verification

    PARP Cancer
    JW 55 is a potent and selective β-catenin signaling pathway inhibitor, which functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2). JW 55 decreases auto-PARsylation of TNKS1/2 in vitro with IC50s of 1.9 μM and 830 nM respectively.
    JW 55
  • HY-147245

    STP1002

    PARP Cancer
    Basroparib (STP1002) is a selective, orally active inhibitor of tankyrase (TNKS1/TNKS2) with IC50 of 29.94 nM and 3.68 nM for TNKS1 and TNKS2, respectively. Basroparib has an IC50 of >10 μM for PARP1. Basroparib binds to TNKS, stabilizes AXIN1/2 proteins, blocks Wnt/β-catenin signaling pathway, inhibits tumor cell proliferation and induces apoptosis, while reducing cancer stem cell properties. Basroparib can be used in colorectal cancer (CRC) studies with KRAS mutations (such as G12V/G12D) to overcome acquired resistance to MEK inhibitors. STP1002 has synergistic antitumor activity with MEK inhibitors .
    Basroparib
  • HY-121719

    PARP Cardiovascular Disease Cancer
    TIQ-A is a potent TNKS (poly-ART, PARP) inhibitor, with an IC50 of 24 nM for TNKS2. TIQ-A is a potential anti-ischemic agent .
    TIQ-A
  • HY-12438
    G007-LK
    5+ Cited Publications

    PARP Cancer
    G007-LK is a potent and selective inhibitor of TNKS1 and TNKS2, with IC50s of 46 nM and 25 nM, respectively.
    G007-LK
  • HY-RS24984

    Small Interfering RNA (siRNA) TNK1 Others

    Tnk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Tnk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Tnk1 Rat Pre-designed siRNA Set A
    Tnk1 Rat Pre-designed siRNA Set A
  • HY-RS14838

    Small Interfering RNA (siRNA) Others

    TNK2 Human Pre-designed siRNA Set A contains three designed siRNAs for TNK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TNK2 Human Pre-designed siRNA Set A
    TNK2 Human Pre-designed siRNA Set A
  • HY-RS18502

    Small Interfering RNA (siRNA) TNK1 Others

    Tnk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Tnk1 Mouse Pre-designed siRNA Set A
    Tnk1 Mouse Pre-designed siRNA Set A
  • HY-RS23371

    Small Interfering RNA (siRNA) Others

    Tnk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Tnk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Tnk2 Rat Pre-designed siRNA Set A
    Tnk2 Rat Pre-designed siRNA Set A
  • HY-RS14837

    Small Interfering RNA (siRNA) TNK1 Others

    TNK1 Human Pre-designed siRNA Set A contains three designed siRNAs for TNK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TNK1 Human Pre-designed siRNA Set A
    TNK1 Human Pre-designed siRNA Set A
  • HY-RS16928

    Small Interfering RNA (siRNA) Others

    Tnk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Tnk2 Mouse Pre-designed siRNA Set A
    Tnk2 Mouse Pre-designed siRNA Set A
  • HY-153332

    PARP Cancer
    Tankyrase-IN-5 (Compound 30f), an analogue of MSC2504877 (HY-123851), is a tankyrase TNKS1 and TNKS2 inhibitor with IC50s of 2.3 nM and 7.9 nM, respectively .
    Tankyrase-IN-5
  • HY-19351
    MN-64
    3 Publications Verification

    PARP Cancer
    MN-64 is a potent tankyrase 1 inhibitor, with IC50s of 6 nM, 72 nM, 19.1 μM, and 39.4 μM for TNKS1, TNKS2, ARTD1 and ARTD2, respectively.
    MN-64
  • HY-108845

    TNK-tPA

    Ser/Thr Protease Cardiovascular Disease
    Tenecteplase (TNK-tPA) is a modified tissue plasminogen activator. Tenecteplase is a recombinant human tissue plasminogen activator (rt-PA) that has been bioengineered to produce mutations in three gene loci. Tenecteplase (TNK-tPA) can be used in the study of acute ischemic stroke .
    Tenecteplase
  • HY-147886
    PARP1-IN-11
    1 Publications Verification

    PARP Cancer
    PARP1-IN-11 (compound 49) is a potent PARP1 inhibitor with IC50 value of 0.082 µM. PARP1-IN-11 shows complete inhibition of PARP2 and substantially inhibits PARP3, TNKS1 and TNKS2 .
    PARP1-IN-11
  • HY-126248

    PARP Wnt Cancer
    Tankyrase-IN-2 (compound 5k) is a potent, selective, and orally active tankyrase inhibitor (IC50s of 10, 7, and 710 nM for TNKS1, TNKS2 as well as PARP1, respectively). Tankyrase-IN-2 has favorable physicochemical profile and pharmacokinetic properties modulating Wnt pathway activity in a colorectal xenograft model .
    Tankyrase-IN-2
  • HY-108516

    Wnt PARP Cancer
    TC-E 5001 is an inhibitor of Wnt pathway that inhibits tankyrase 1/2 (TNKS1/2) via novel adenosine pocket binding, with Kds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits Axin2 and STF, with IC50s of 0.709 μM and 0.215 μM, respectively .
    TC-E 5001
  • HY-12975
    AZ6102
    1 Publications Verification

    PARP Cancer
    AZ6102 is a potent dual TNKS1 and TNKS2 inhibitor, with IC50s of 3 nM and 1 nM, respectively, and alao has 100-fold selectivity against other PARP family enzymes, with IC50s of 2.0 μM, 0.5 μM, and >3 μM, for PARP1, PARP2, and PARP6, respectively.
    AZ6102
  • HY-15147
    XAV-939
    Maximum Cited Publications
    169 Publications Verification

    β-catenin PARP Cancer
    XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation .
    XAV-939
  • HY-16910
    WIKI4
    4 Publications Verification

    PARP β-catenin Wnt Cancer
    WIKI4 is a potent tankyrase inhibitor with an IC50 of 26 nM for TNKS2. WIKI4 potently inhibits Wnt/β-catenin signaling and that its half-maximal response dose is 75 nM. WIKI4 mediates its effects on Wnt/β-catenin signaling by inhibiting the enzymatic activity of TNKS2 . WIKI4 is cytotoxic to SCLC cells with an IC50 value of 0.02 μM .
    WIKI4
  • HY-152197

    PARP Cancer
    Tankyrase-IN-3 is a tankyrase 1 (TNKS1) inhibitor with an IC50 value of 22 nM. Tankyrase-IN-3 can be used for the research of cancer .
    Tankyrase-IN-3
  • HY-145267

    PARP Wnt Cancer
    OM-153 is a potent and orally active tankyrase inhibitor with IC50s of 13 nM and 2 nM for tankyrase 1 and tankyrase 2 (TNKS1/2), respectively. OM-153 inhibits luciferase-based Wnt/β-catenin signaling reporter activity with an IC50 value of 0.63 nM. OM-153 shows inhibition of Wnt/β-catenin signaling and proliferation in COLO 320DM .
    OM-153
  • HY-152198

    PARP Cancer
    Tankyrase-IN-4 is a tankyrase 1 (TNKS1) inhibitor with an IC50 value of 0.8 nM. Tankyrase-IN-4 can be used for the research of cancer .
    Tankyrase-IN-4
  • HY-15811

    ACK1-B19

    Tyrosinase Cancer
    XMD8-87 is a potent TNK2 inhibitor with IC50 values of 38 and 113 nM for the D163E and R806Q mutations, respectively.
    XMD8-87
  • HY-101243

    Tyrosinase Cancer
    XMD16-5 is a potent TNK2 inhibitor with IC50 values of 16 and 77 nM for the D163E and R806Q mutations, respectively.
    XMD16-5
  • HY-147316

    STAT TNK1 Cancer
    TP-5801 is an orally active TNK1 (non-receptor tyrosine kinase) inhibitor (IC50=1.40 nM), and shows anti-tumor activity .
    TP-5801

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: